Sentences with phrase «cell and gene therapy including»

Experts in pediatric oncology, pediatric surgery, cell and gene therapy including stem cell transplant, radiation oncology, pediatric anesthesia, pharmacology, social work, child life and the full complement of pediatric subspecialty services put a strong focus on family - centered care and emotional support for both the child and the family.

Chris is on a number of national and international committees, working groups and initiatives related to the academic, clinical translation and commercialization of cell and gene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell Network.

Not exact matches

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmCell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develTherapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmcell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmcell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

They include going after the damage to cells done by free radicals, making use of hormone therapy, or caloric restrictions, or vitamin supplements, or, most dramatically, healthy gene selection through pre-implantation genetic diagnosis and even repairing the entire human genome.

New treatments for spinal cord injury, including stem cells, gene therapy and electrical stimulation, are being studied.

These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.

For his part, Collins, who has led NIH since 2009 and been kept on by the Trump administration, pointed to an array of promising NIH activities, including the development of new technologies to provide insights into human brain circuitry and function through the Brain Research through Advancing Innovative Neuroethologies (BRAIN initiative) and the use of the gene - editing tool CRISPR - Cas9 to correct mutations and clear the way to develop and test a «curative therapy» for the first molecular disease: sickle cell disease.

FDA also approves so - called biologics, which include products made from human tissues, blood, and cells, and gene therapy techniques.

The results, published in the current issue of Human Molecular Genetics, open the door for pursuing gene editing in nonhuman primates as models for new therapies, including pharmacological, gene - and stem cell - based therapies, said Keith Latham, MSU animal science professor and lead author of the study.

Other blood disorders that have shown significant benefit from targeted gene therapy in small trials include hemophilia (specifically, factor IX deficiency), severe beta - thalassemia (deficiency for the adult beta - globin gene) and leukemia, where the patient's immune cells were treated to enable them to recognize cancer cells and destroy them.

The vector is a self - inactivating lentivirus — a member of a family of viruses that can insert genes into mammalian cells and drive expression of those genes — that has been engineered to avoid triggering the development of leukemia, a complication seen in previous gene therapy trials for immunodeficiency syndromes, including WAS.

Colleen Dansereau, RN, MSN, CPN Program Manager, Gene Therapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (CGene Therapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous diseaseTherapy Program As manager of the Gene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (CGene Therapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous diseaseTherapy Program, Colleen administratively manages the CAR T - cell therapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous diseasetherapy program as well as all administrative responsibility for all of the gene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (Cgene therapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous diseasetherapy clinical trials that take place at Dana - Farber / Boston Children's, for conditions including sickle cell disease, Wiskott - Aldrich Syndrome (WAS), and chronic granulomatous disease (CGD).

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

He is a general spokesperson for the cell and gene therapy sector including frequent newspaper, radio and TV interviews.

Supported by: Hear from leading expert Dr David DiGiusto, Stanford University School of Medicine, USA, as he shares his extensive experience in developing and optimizing manufacturing processes for cell and gene therapy products including:

Dr. Semenza's research interests include the molecular mechanisms of oxygen homeostasis; gene and stem cell therapy for ischemic cardiovascular disease; the role of HIF - 1 in cancer; and protection of the heart against ischemia - reperfusion injury.

Important reports from the Weiner lab include the first DNA vaccine studied for HIV as well as for cancer immune therapy of cutaneous T cell lymphoma, the early development of DNA encoded genetic adjuvants, including IL - 12, advances in gene optimization, and advances in electroporation technologies resulting in improved gene delivery.

Native viral vectors can be therapeutics themselves, but they also function as a critical input to manufacturing rapidly emerging therapeutic platforms, including CAR - T and other forms of gene - modified whole - cell therapies.

Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world's largest efforts to preclinically validate potential therapeutics; including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell - based constructs.

In addition to its emphasis on producing vaccines, the lab specializes in gene and cell therapies, including stem cell products.

Distilling the most radical accomplishments being made in labs worldwide, including gene therapy, genetic engineering, stem cell research, life extension, brain - computer interfaces, and cloning, More Than Human offers an exciting tour of the impact biotechnology will have on our lives.

There are several different treatments being compared, including: surgery followed by vaccine - based immunotherapy, surgery followed by oncolytic virus therapy, surgery followed by IL - 12 gene therapy and biopsy followed by placement of a specialized catheter system that draws tumor cells out of the brain.

Faculty research interests and expertise include mechanisms of metastasis in cancer; gene therapy (including electroporation) in cancer; cell and molecular biology of tooth eruption; pharmacology and toxicology of aquatic species; environmental and ecological toxicology; cellular ultrastructure; environmental risk assessment; analytical pharmacology and toxicology; diagnostic neurophysiology; pharmacology of pain and inflammation; exercise physiology; xenobiotic metabolism and disposition; neurochemistry; pulmonary pharmacology; cardiovascular disease; and cetacean morphology.

Preparation and global prosecution of patent applications directed to diagnostic and therapeutic products including antibodies, gene therapies, vaccines, stem cells, pharmaceutical formulations, nanotechnology, nucleic acid molecules, biologics, medical devices, mouse platforms for antibody development, and methods of treating diseases.